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1. INTRODUCTION 
The rennin–angiotensin system acts through two factors, 
i.e. angiotensin-converting enzyme, which converts 
angiotensin I to angiotensin II, and angiotensin receptors I 
and II to maintain volume homeostasis, control blood 
pressure and prevent ischemia.Therefore, controlling both 
the factors simultaneously provides effective blood 
pressure control and reduces the risk of cardiovascular 
events. 
Ramipril and ramiprilat compete with angiotensin I and 
block the conversion of angiotensin I to angiotensin II. 
Angiotensin II contracts the muscles of most arteries in the 
body, including the heart, thereby narrowing the arteries 
and elevating the blood pressure. Ramipril is chemically  
designated as (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-
oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-
hexahydro-2H-cyclopenta[d]pyrrole-2-carboxylic acid. 
Ramipril and ramiprilat structure showed in Fig.1.             
A number of methods have been reported for the 
simultaneous determination of ramipril and ramiprilat, 
including liqu id chromatography with tandem mass 
spectrometric  detection (LC–MS/MS) using liquid–liquid  
extraction, GC–MS using derivatisation technique and 
high-performance liquid chromatography (HPLC). 
Although the above methods are fast and robust, they 
require a large number of complicated steps for sample 
pretreatment. 
LC–MS/MS was demonstrated to be superior to all the 
above mentioned techniques in terms of sensitivity, 
selectivity, simplicity and analysis throughput. This paper 
describes the LC technology coupled with triple quadruple 
tandem mass spectrometry that has been applied to the 
analysis for the simultaneous determination of ramipril  and 
ramiprilat using enalapril as the internal standard (IS). The 
use of solid phase extraction technique (SPE) using plexus 
cartridges  30mg 1cc from Analchem Inc. (IL, USA) 
reduced the background noise produced by electrospray 
ionization (ESI), enabling us to develop a single and more 
sensitive method for ramipril and ramiprilat with a high 
sample throughput due to the short chromatographic 
condition and simple sample preparat ion. 
 
               Ramipril                               Ramiprilat 
 Figure1: Chemical structure of Ramipril and Ramiprilat 
 
2. MATERIALS AND METHODS  
2.1. Chemicals and reagents  
Ramipril, ramiprilat and enalapril standards (purity > 
99.8%) were obtained from Varda Biotech (India). Tri-
potassium salts of ethylenediaminetetraacetic acid 
(K3EDTA) plasma of healthy volunteers were obtained 
from In-house Clinic Cliantha Research, Ahmedabad 
(India). Acetonitrile (HPLC grade) and methanol were 
obtained from Qualigens, Germany. Milli-Q water 
(Millipore Co., MA, and USA) purification system was 
used to obtain purified water for the HPLC analysis. 
2.2. Instrumentation 
Chromatography was performed at ambient temperature, 
with the mobile phase consisting of acetonitrile  and 
deionised water (65:35, V/V) plus 1.0mLL-1 ammonium 
ABSTRACT 
A rapid and sensitive liquid chromatography tandem mass spectrometry method has been developed and validated for the 
simultaneous determination of ramipril and ramiprilat in human plasma. The solid-phase extraction technique was used for the 
extraction of ramipril and ramiprilat from human plasma. Enalapril was used as the internal standard (IS).Chromatography 
was performed on a Aquasil C18, 100mm×2.1mm, 5µ column, with the mobile phase consisting of acetonitrile-deionsed water 
(in a 65:35 ratio) and 1.0mLL-1 ammonium trifluoroacetate solution (1.0M), followed by detection using mass spectrometry. 
The method involves a simple reversed isocratic chromatography condition and mass spectrometry detection, which enables 
detection at sub-nanogram levels. The method was validated and the lower limit of quantification for ramipril and ramiprilat 
was found to be 0.1 ngmL−1and 0.1 ngmL−1, respectively. The mean recovery for ramipril and ramiprilat ranged from 63.5 to 
74.3%. This method increased the sensitivity and selectivity; resulting in high-throughput analysis of ramipril and ramiprilat 
using single IS in a single experiment for bioequivalence studies, with a chromatographic run time of 3.0 min only. 
Key words: Ramipril, Human Plasma, Solid-phase extraction technique, ESI-LC-MS/MS 
 
Sompura et al                       Journal of Drug Delivery & Therapeutics; 2012, 2(3): 153-158    154 
© 2011, JDDT. All Rights Reserved                                         ISSN: 2250-1177                                  CODEN: JDDTAO 
trifluaroacetate solution (1.0M). An Aquasil C18 
(100mm×2.1mm, 5µ) column obtained from Thermo 
Hypersil, FL, USA, was used for the chromatographic 
separation at a flow rate of 0.3 mL/min. The mobile phase 
was delivered by a high performance liquid  
chromatography (HPLC) pump and the sample was 
injected by a HPLC autosampler (Schimadzu, JAPAN). 
Detection was performed by an API-4000 LC-MS/MS 
tandem quadrupole mass spectrometer (AB SCIEX, USA) 
fitted with an ESI source operating in a positive ion mode.  
A Plexus 30mg/1cc solid-phase extract ion (SPE) cartridge 
for sample preparation was obtained from Analchem.  
Mass spectra were obtained using a Sciex API 4000 mass 
spectrometer equipped with a turbo ion-spray source. The 
data acquisition was ascertained by Analyst 1.4.2 software. 
The mass spectra of ramipril, ramiprilat and its internal 
standard enalapril are presented in Fig. 2. The strongest 
fragment of each compound, as indicated in Fig. 2 was 
selected and used as Q3 ion to be monitored. The mass 
transition ion-pair was selected as follows: 417.2→234.1 
for ramipril, 389.2→206.1 for ramiprilat and 377.2→234.2 
for enalapril. 
 
 
 
 
Figure 2: Representative mass spectra of ramipril, ramiprilat, enalapril and fragment ion 
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Mass detection was obtained at a unit-mass resolution for 
all channels Quantitation of ramipril and ramiprilat in  
human plasma was based on the peak area ratios of 
ramipril versus its internal standard enalapril and 
ramiprilat versus enalapril.  
2.3. Preparation of standards and quality control  
samples 
The stock solutions of ramipril, ramiprilat and internal 
standard enalapril were ind ividually prepared in methanol 
at a concentration of 100µg/ml. Dilutions of 2.000/2.000 
ng/mL to 500.0/500.0 ng /mL were made from the stock 
solutions of ramipril and ramiprilat. These diluted 
solutions were used to prepare the calibration curve and 
quality control samples.  
Blank human plasma was screened prior to spiking to 
ensure it was free of endogenous interference at the 
retention times for ramipril, ramiprilat and internal 
standard. A ten-point standard curve of ramipril and 
ramiprilat was prepared by spiking the blank plasma with 
appropriate amounts of ramipril and ramiprilat. The 
calibrat ion curve ranged from 0.1 to 25.00 ng / ml fo r both 
ramipril and ramiprilat. Quality control samples were 
prepared at four concentration levels of 0.3, 2.5, 10.0 and 
18.75 ng / ml for both ramipril and ramiprilat and in a 
manner similar to the standard from the stock solution. A 
weighted least-squares linear regression was used for 
quantitation of ramipril and ramiprilat in this study and the 
weighting factor was 1 /x
2
. 
2.4. Extraction procedure  
A 0.5mL aliquot of human plasma sample was mixed with 
100 µL of internal standard working solution (50.00 ng/ml 
of enalapril in deionized water) and then added 25µL of 
25% orthophosphoric acid solution vortex to mix. The 
sample mixture was loaded into a Plexus extract ion 
cartridge that was pre-conditioned with 1 ml methanol 
followed by 1 ml deionized water. Centrifuge for 1.0 
minute at 3000 rpm for each step. The extraction cartridge 
was washed with 1 mL of deionized water. Ramipril, 
ramiprilat and internal standard were eluted with 1 mL 
methanol by centrifugation for 1.0 minute at 3000 rpm and 
evaporated to dryness under a gentle stream of nitrogen 
(40ºC). The extracted residues were dissolved in 0.3 ml of 
reconstitution solution; 10 µL of reconstituted sample was 
injected into the LC/MS/MS system. 
2.5. Validation 
The method has been validated for selectivity, linearity, 
precision, accuracy, recovery and stability. The accuracy 
was determined by replicate analysis of samples containing 
known amounts of analytes. The intra-assay precision and 
accuracy was determined with six rep licates of LLOQ, 
ULOQ and quality control samples (HQC, MQC-1, MQC-
2 and LQC) at each level that were extracted from the 
sample batch. The inter-assay precision and accuracy was 
determined by analyzing the quality control samples that 
were tested on three different occasions. Inter-assay and 
intra-assay precision and accuracy evaluations were based 
on back-calculated concentrations. 
The selectivity is the ability of an analyt ical method to 
differentiate and quantify the analyte in the presence of 
other components in the sample. This test was performed  
by analyzing the blank plasma samples from different 
sources (or donors) to test for interference at the retention 
time of ramipril, ramiprilat and internal standard. 
The relative recovery of ramipril and ramiprilat was 
evaluated by comparing the peak area response of 
extracted analytes and internal standard with that of 
reference quality control solutions at the same 
concentration level and reconstituted into blank plasma 
extracts. 
The stability of drugs in human plasma was studied by 
subjecting into different storage conditions at two different 
concentration (LQC and HQC) levels. The plasma samples 
were kept at room temperature for 25 h for evaluation of 
bench top stability. And −20º ± 10ºC as well as -70º ± 
20ºC for long term freezer stability. Freeze/thawed 
stability was also evaluated after subjecting into six cycles 
of freezing and thawing. The stability was evaluated by 
comparing with a freshly prepared calibration standard and 
QC samples. 
All stability evaluations were based on back-calculated 
concentrations.  
Table 1: Back Calculated concentration of ramipril and ramiprilat (n=4). 
SD: standard deviation; n: total number of observation; STD: standard 
 Concentration (ngmL-1) 
STD-1            STD-2           STD-3           STD-4              STD-5            STD-6            STD-7            STD-8           STD-9           STD-10                                        
      0.1                  0.2                   0.5                1.0               2.0                       5.0                9.0                   15.0                20.0             25.0 
Ramipril 
Mean  
S.D. 
% CV 
Accuracy (%) 
Slope = 0.232436                Intercept  =-0.000731827                   r
2
=0.9994613 
0.09966         0.2011                0.4988              1.008               2.018              4.981                9.102             14.78          20.39            24.29                 
0.00065         0.0015               0.0134               0.0283              0.0371           0.244                0.2957           0.5446       0.4975         0.6763 
0.7                   0.8                       2.7                    2.8                    1.8                   4.9                      3.2                 3.7             2.4             2.8 
99.7                 101                     99.8                   101                   101                   99.6                   101               98.5            102           97.2 
Ramiprilat 
Mean  
S.D. 
% CV 
Accuracy (%) 
Slope =0.0273276       Intercept  =0.000071752        r
2
=   0.9989181 
0.09911        0.2033                0.5051               1.003                1.916             5.175              9.102                14.42          20.09           25.26             
0.00073        0.0037                0.0219               0.0522              0.0410           0.154             0.3551              0.9846       0.5490         0.7687 
0.7                      1.8                      4.3                     5.2                    2.1                3.0                   3.9               6.8             2.7                3.0 
99.1                  102                     101                    100                      95.8               104                101                96.1          100                101 
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3. RES ULTS  
3 .1 Limit of quanti tation, linearity and precision 
The limit of quantitation (LOQ) fo r ramipril and ramiprilat in human plas ma is 0.1 ng/ mL. The calcu lation was based on 
the peak area rat io of analyte versus its internal standard. The calibration curves are linear in the concentration range 
0.1000–25.00 ng/mL for both ramipril and ramiprilat. The results of the calibration samples are presented in Table 1. The 
average correlation co-efficient were 0.9994 for ramipril and 0.9989 for ramiprilat. The inter-batch precision and accuracy 
were determined from three analytical batches by analyzing spiked QC samples. The intra-batch precision and accuracy of 
the assay were measured by analyzing six spiked samples of ramipril and ramiprilat at each QC level (0.3, 2.5, 10.0 and 
18.75 ngmL−1 of ramipril and ramiprilat). Intraday and inter-day precision ranged from 1.4 to 3.1% and 2.5 to 5.3% for 
ramipril, 2.8 to 13.0% and 4.1 to 8.3% for ramiprilat while accuracy  was within 97.9 to 104% and 99.7 to 102% for 
ramipril, 94.7 to 104% and 96.2 to 103% for ramiprilat respectively, as given in Table 2.  
Table 2: Intraday and inter day accuracy of method for ramipril and ramiprilat  
Levels               Conc Added    
                             (ngmL
-1
) 
Intra day Inter day 
n        Mean conc        Accuracy(%)         % CV found 
          (ngmL
-1
)
a 
n         Mean Conc            Accuracy(%)         % CV found  
           (ngmL
-1
)
b
 
Ramipril 
LLOQ                   0.1000 
LQC                      0.3000 
MQC-2                   2.500 
MQC-1                   10.00 
HQC                       18.75 
 
6      0.1043                 104                       2.1 
6      0.3062                 102                       2.6 
6      2.553                   102                       3.1 
6      10.11                   101                       1.4 
6      18.36                   97.9                      1.4 
 
18      0.1024                     102                         2.9 
18      0.3074                     102                         2.5 
18      2.493                        99.7                        5.3 
18      10.19                       102                         3.0 
18      19.07                       102                         4.7 
Ramiprilat 
LLOQ                   0.1000 
LQC                     0.3000 
MQC-2                   2.500 
MQC-1                   10.00 
 HQC                      18.75 
 
6      0.09472              94.7                      13.0 
6      0.3186                104                         7.3 
6      2.467                  98.7                        4.2 
6      9.723                  97.2                        7.2 
6      18.44                  98.3                        2.8 
 
18      0.09623                    96.2                        8.3 
18      0.3076                     103                         6.1 
18      2.491                       99.6                        5.4 
18      9.928                       99.3                        6.1 
18      18.48                       98.6                        4.1 
CV, coefficient of variance; n, total number of observation, 
a Mean of  6 replicates observation at each concentration,      b Mean of  18 replicates observations over three different analytical batch. 
3 .2 Selectivity 
A representative chromatogram of extracted blank plasma 
is presented in Fig. 3. Representative chromatograms of 
extracted plasma samples containing 0.1 ng/mL (low 
standard) and 25.00 ng/mL (h igh standard) ramipril and 
ramiprilat are presented in Figs. 4 and 5. Six different 
sources of drug free human plasma samples were screened 
and no endogenous interference was observed at the 
retention times of ramipril, ramiprilat and internal 
standard.
 
 
 
Figure 3: Representative chromatograms of extracted blank p lasma samples.  
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Figure 4: Representative chromatograms of extracted plasma sample containing 0.1000 ngmL
-1 
both ramipril and ramiprilat 
(LLOQ). 
 
 
Figure 5: Representative chromatograms of extracted plasma sample containing 25 ngmL-1 both ramipril and ramiprilat (ULOQ) 
3 .3 Recovery 
The recovery was based on the comparison of the peak 
areas of extracted plasma QC samples at low 
0.5000/0.5000 ngmL
-1  
 (LQC), Medium 2.500/2.500 
ngmL
-1  
 (MQC-2) and 10.00/10.00 ngmL
-1  
 (MQC-2) and 
high 18.75/18.75 ngmL
-1  
 concentration with unextracted 
QC samples for each concentration, the peaks areas of six 
(6) replicates of extracted and unextracted  samples were 
compared. The mean recovery and precision (%CV) of 
ramipril/ramiprilat from plas ma was 63.5%/74.3% and 
1.4%/2.2% respectively. The mean recovery and precision 
(%CV) of internal standard from plasma was 76.1% and 
3.2% respectively. 
Table 3: Matrix effect evaluation for ramipril and ramiprilat (n=4)  
 Concentration ng mL
-1
 
HQC     HQC      HQC      HQC       HQC      HQC                 LQC        LQC      LQC        LQC         LQC      LQC 
LO T-1   LO T-2   LO T-3    LO T-4     LO T-5   LO T-6               LO T-1     LO T-2   LO T-3      LO T-4     LO T-5   LO T-6 
Ramipril 
Mean  
S.D.   
%CV 
 
18.11     18.23      17.13      18.12     18.30      18.08                 0.2998     0.2917    0.2928     0.2919       0.2938    0.2997 
0.118     0.486      0.206      0.302     0.588      0.342                 0.0103     0.0158    0.0177     0.0106      0.0050    0.0125   
 0.7        2.7          1.2          1.7          3.2         1.9                     3.4           5.4          6.0           3.6           1.7          4.2 
Ramiprilat 
Mean  
S.D. 
%CV 
 
17.98    18.53     18.32      18.08      17.26     18.16               0.2970      0.2938      0.2965     0.2936     0.2966     0.3021    
0.282    0.2193   0.460      0.246      0.256     0.419               0.0117      0.0133      0.0087     0.0078     0.0054     0.0259    
 1.6        1.2        2.5          1.4         1.5          2.3                   3.9            4.5            2.9           2.7           1.8           8.6      
 
3. 4 Matrix Effect 
There were four sets of QC samples for ramipril/ramiprilat  
at high (18.75/18.75) (HQC) and low (0.3000/0.3000) 
(LQC) concentration injected using six different p lasma 
matrices to study the matrix effect. The precision (%CV)  
for the plasma matrices for HQC and LQC concentration 
QC samples were in the range of 0.7%/1.2% to 3.2%/2.5% 
and 1.7%/1.8% to 6.0%/8.6% respectively for 
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ramipril/ramiprilat. These results indicate that there is no 
significqant matrix effect. Tab le 3 shows  the statistical 
data of the results. 
3 .5 Stability 
3.5a Freeze thaw Stability 
QC samples (20 sets) prepared at high (HQC) and low 
(LQC) concentration were divided into 5 cycles consisting 
of 4 sets of QC samples per cycle. Init ial 4 sets of QC 
samples were stored at -20ºC±10ºC for at least 24 hours 
and were thawed at room temperature in a water bath for 
minimum of 2 hours; subsequent QC samples were 
refrozen for at least 12 hours under the same conditions. 
Samples from all six freeze and thaw cycles were ext racted 
and compared against a fresh calibration standard curve. 
The observed values were compared against the nominal 
values. The results indicated that the samples were stable 
for at least six freeze thaw cycles. 
3.5b Bench Top Stability  
Six sets of plasma QC samples at high (HQC) and low 
(LQC) for ramipril and ramiprilat were kept at room 
temperature for 25 hours. After 25 hours, the samples were 
extracted and injected using fresh calibration standard 
curve. The results indicated that the plasma samples were 
stable at room temperature for at least 25 hours. 
3.5c Processed sample stability at room temperature 
Concentration of extracted replicates was compared to the 
nominal concentration. The results showed that ramipril 
and ramiprilat was stable for at least 96 hours at room 
temperature after ext raction and sample preparation and 
prior to sample analysis. 
3.5c Processed sample stability at refrigerator 
temperature 
The concentration of extracted replicates to the nominal 
concentration are Compared. The result showed that 
ramipril and ramiprilat samples were stable during storage 
in the refrigerator (4ºC±6ºC) for at least 96 hours. 
4 APPLICATION OF THE METHOD 
The method was applied to the analysis of plasma samples 
obtained from pharmacokinetic study. The study was 
conducted as a randomized, single-dose, two treatments, 
two-sequence, two-period, crossover study with at least 21 
days washout period between each administration, in 48 
healthy adult male human subjects under fasting condition. 
Each subject received ramipril 2.5 mg tablet of test or 
reference. Blood samples were collected using K3EDTA 
vaccutainers at the following times: pre-dose, 0.0, 0.167, 
0.333, 0.50, 0.667, 0.833, 1.0, 1.25, 1.50, 2.0, 2.5, 3.0, 4.0, 
5.0, 6.0, 8.0, 12.0, 16.0, 24.0 Ambulatory sample (48.0, 
72.0, 96.0 & 120.0) hours post dose after administration.  
Pharmacokinetic parameters were calculated from the 
subjects who had successfully completed period I and 
Period II. 
5. CONCLUS ION 
A highly sensitive and selective method for the 
simultaneous determination of ramipril and ramiprilat was 
developed using HPLC-MS/MS with turbo-ESI. Th is 
developed assay method was used in a pharmacokinetic 
study in which 48 healthy male volunteers were given a 
2.5mg of ramipril.This method allows for a much higher 
sample throughput due to short chromatographic time (3.0 
min) and simple sample p reparation. This validated 
method is an excellent analytical option for simultaneous, 
rapid quantification of ramipril and ramiprilat in human 
plasma. 
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